Caris Life Sciences expands pathology practice to urology
Caris Life Sciences (Irving, TX) has announced the launch of its urologic pathology practice, available through its subsidiary Caris Diagnostics.
Caris Life Sciences (Irving, TX) has announced the launch of its urologic pathology practice, available through its subsidiary Caris Diagnostics.
Under the leadership of Rajal B. Shah, MD, Caris’ urologic pathology experts will also support the development of a proprietary testing platform that will help diagnose and manage prostate cancer patients earlier and less invasively.
"Caris’ commitment to precise and personalized health care begins with investment in subspecialty physician expertise," said Richard H. Lash, MD, of Caris Life Sciences. "Our urologic pathology services will mirror our other subspecialty practices with a commitment to academic activities, including research and education, combined with unsurpassed service and the latest evidence-based molecular testing."
Dr. Shah, who joined the company in January 2010, has been named director of Caris’ Urologic Pathology Services. Dr. Shah joined Caris from the University of Michigan, Ann Arbor, where he served as clinical associate professor of urology and pathology, as well as director of the Urologic Pathology Service and fellowship program.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
